# Sporos Bioventures

Sporos Bioventures is a Venture Capital based in Houston, United States.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Houston, United States
- **Region:** North America
- **Address:** 3139 West Holcombe Blvd, Houston, TX 77025, United States
- **Founded:** 2020
- **Assets under management:** Undisclosed
- **Website:** www.sporosbioventures.com
- **LinkedIn:** https://www.linkedin.com/company/sporos-bioventures

## Regulatory record

- **Reports private funds:** No

## About

Sporos Bioventures, LLC is a private biotechnology company focused on transforming the drug development process across oncology through its portfolio approach. It catalyzes the rapid development of breakthrough therapies through a portfolio of companies that target novel disease mechanisms in cancer, fibrosis, inflammation, and immune-related diseases. Its pipeline of assets focuses on oncology and immune-related diseases and is generated through external partnerships and its internal biodiscovery platform. The company is headquartered in Houston with operations in New York and Boston.

## Sectors

- Healthcare Services

## People

- Alex Cranberg — Founder, Aspect Energy
- Rachel Humphrey — CEO, Normunity
- Harold Levy — Co-CIO, Iridian Asset Management
- Peter Feinberg — Founding Partner, Boxcar Partners

## Questions

### How is Sporos Bioventures structured — is it a fund or an operating company?

Sporos Bioventures is a private biotechnology company that holds equity interests in multiple biopharma entities. It does not present itself as a traditional venture fund with limited partners; rather, it functions as a holding entity with portfolio companies Tvardi Therapeutics and Sporos BioDiscovery. This structure avoids standard fund-life constraints, allowing it to support long-duration oncology development programs.

### What is Sporos Bioventures' investment strategy in oncology?

Sporos focuses on developing targeted cancer treatments by attacking cancer-specific vulnerabilities and co-dependencies found in the tumor microenvironment. Its portfolio approach — holding equity in multiple drug-development entities rather than a single company — is designed to diversify scientific risk across different therapeutic programs. This differentiates it from a typical single-asset biotech startup.

### Does Sporos Bioventures invest in anything besides oncology?

No. All disclosed portfolio companies — Tvardi Therapeutics and Sporos BioDiscovery — are exclusively engaged in oncology drug development. The firm's published materials contain no mention of investments in other therapeutic areas or sectors outside life sciences.

## Related profiles

- [SponsorCircle](https://altss.com/profile/sponsorcircle)
- [Sport Horizon Holding](https://altss.com/profile/sport-horizon-holding)

---

Last updated: 2026-08-11T15:08:11.274Z

Canonical page: https://altss.com/profile/sporos-bioventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology